LyudmilaA.BazhenovaMD

Oncology • San Diego, CA

Thoracic Cancer

Moores UCSD Cancer Center

Join to view full profile

Dr. Bazhenova is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Bazhenova's full profile

Already have an account?

Office
200 W Arbor Dr
San Diego, CA 92103
Phone+1 858-822-6100

Fax+1 858-822-6190

Summary

Dr. Lyudmila Bazhenova is a Medical Oncologist at the University of California San Diego, specializing in Thoracic Cancer. Dr. Bazhenova is a prominent clinical trialist, focusing her research on drug development for thoracic malignancies. She serves as an institutional Principal Investigator and a Respiratory Committee Member of the NCI-funded Alliance for Clinical Trials in Oncology Cooperative group. Dr. Bazhenova has been recognized for her national reputation as a clinical trialist with the NCI Clinical Trial Leadership Award. She has authored over a hundred manuscripts on thoracic malignancies including national guidelines on mesothelioma and lung cancer management

Education & Training

Scripps Clinic/Scripps Green HospitalFellowship, Hematology and Medical Oncology, 2002 - 2005
UCLA-VA Greater Los AngelesResidency, Internal Medicine, 1999 - 2002
Nizhny Novgorod State Medical Academy Class of 1994

Certifications & Licensure

CA State Medical License 2001 - 2025
American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2011-2013
Super Doctor SuperDoctors.com

Clinical Trials

Study Evaluating the Addition of Fulvestrant to Erlotinib in Stage IIIB/IV Non-Small Cell Lung Cancer Start of enrollment: 2007 Sep 01
Terminated
Phase 2
Safety and Efficacy of BKM120 in Patients With Metastatic Non-small Cell Lung Cancer Start of enrollment: 2011 May 01
Completed
Phase 2
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Anti-Tumor Activity of the Oral Anaplastic Lymphoma Kinase (ALK)/Epidermal Growth Factor Receptor (EGFR) Inhibitor Brigatinib (AP26113) Start of enrollment: 2011 Sep 20
Completed
Phase 1, Phase 2
LDK378 in Adult Patients With ALK-activated NSCLC Previously Treated With Chemotherapy and Crizotinib Start of enrollment: 2012 Nov 26
Completed
Phase 2
LDK378 in Crizotinib naïve Adult Patients With ALK-activated Non-small Cell Lung Cancer Start of enrollment: 2012 Dec 20
Completed
Phase 2
A Study of AT13387 in Patients With Non-Small Cell Lung Cancer (NSCLC) Alone and in Combination With Crizotinib Start of enrollment: 2012 Oct 01
Completed
Phase 1, Phase 2
Circulating Tumor Cells in Non-Small Cell Lung Carcinoma Start of enrollment: 2012 Nov 01
Completed
A Study of Emibetuzumab in Non Small Cell Lung Cancer (NSCLC) Participants Start of enrollment: 2013 Aug 01
Completed
Phase 2
Expanded Treatment Protocol With LDK378 in ALK(+) NSCLC
No longer available
A Study to Evaluate the Efficacy of Brigatinib (AP26113) in Participants With Anaplastic Lymphoma Kinase (ALK)-Positive, Non-small Cell Lung Cancer (NSCLC) Previously Treated With Crizotinib Start of enrollment: 2014 Jun 04
Completed
Phase 2
A Study of Abemaciclib (LY2835219) in Participants With Previously Treated KRAS Mutated Lung Cancer Start of enrollment: 2014 Oct 03
Active, not recruiting
Phase 3
Lung-MAP: Biomarker-Targeted Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung Cancer Start of enrollment: 2014 Jul 08
Completed
Lung-MAP: Taselisib as Therapy in Treating Patients With Stage IV Squamous Cell Lung Cancer and Positive Biomarker Matches Start of enrollment: 2014 Nov 01
Completed
Phase 2
Lung-MAP: Palbociclib as Second-Line Therapy in Treating Cell Cycle Gene Alteration Positive Patients With Recurrent Stage IV Squamous Cell Lung Cancer Start of enrollment: 2014 Sep 01
Completed
Phase 2, Phase 3
Lung-MAP: Nivolumab With or Without Ipilimumab as Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung Cancer and No Matching Biomarkers Start of enrollment: 2015 Dec 29
Active, not recruiting
Phase 3
A Safety Study of SGN-2FF for Patients With Advanced Solid Tumors Start of enrollment: 2017 Feb 23
Terminated
Phase 1
Nivolumab in Combination With Plinabulin in Patients With Metastatic Non-Small Cell Lung Cancer (NSCLC) Start of enrollment: 2016 Aug 29
Active, not recruiting
Phase 1
Roles: Contact, Sponsor-Investigator, Principal Investigator
Join now to see all

Publications & Presentations

PubMed

280 citations
Adagrasib in Non-Small-Cell Lung Cancer Harboring aMutation.
Pasi A Jänne, Gregory J Riely, Shirish M Gadgeel, Rebecca S Heist, Sai-Hong I Ou
The New England Journal of Medicine. 2022-07-14
118 citations
First-in-Human Phase I/IB Dose-Finding Study of Adagrasib (MRTX849) in Patients With AdvancedSolid Tumors (KRYSTAL-1).
Sai-Hong Ignatius Ou, Pasi A Jänne, Ticiana A Leal, Igor I Rybkin, Joshua K Sabari
Journal of Clinical Oncology. 2022-08-10
339 citations
NCCN Guidelines ® Insights: Non-Small Cell Lung Cancer, Version 4.2016 Featured Updates to the NCCN Guidelines
David S. Ettinger, Douglas E. Wood, Wallace Akerley, Lyudmila Bazhenova, Hossein Borghaei
Journal of the National Comprehensive Cancer Network. 2016-03-01

Lectures

A phase III randomized study of nivolumab plus ipilimumab versus nivolumab for previously treated patients with stage IV squamous cell lung cancer and no matching biom...
2019 ASCO Annual Meeting - 6/1/2019

Authored Content

Efficacy of Selpercatinib in RET Fusion–Positive Non–Small-Cell Lung CancerAugust 2020
Efficacy of Selpercatinib in RET Fusion–Positive Non–Small-Cell Lung CancerAugust 2020
Efficacy of Selpercatinib in RET Fusion–Positive Non–Small-Cell Lung CancerAugust 2020

Press Mentions

Cancer Status Report: Overall Death Rate Continues to DropJanuary 15th, 2022
Lung-MAP: A Five-Year Recap on the First Master Protocol Trial in Cancer ResearchFebruary 21st, 2020
Breathing in Life with Stage IV Lung CancerNovember 26th, 2019
Join now to see all